No Data
No Data
Capricor Therapeutics Set to Join Russell 2000 and Russell 3000 Indexes
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today
Capricor Therapeutics (CAPR) Gets a Buy From Oppenheimer
What's Going On With Capricor Therapeutics Stock Friday?
Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares are trading higher on Friday. The company announced the long-term benefits of deramiocel for the treatment of duchenne muscular dystrophy (DMD).What Ha
Capricor Therapeutics Rises on Muscular Dystrophy Treatment Study
By Victor Swezey Shares of Capricor Therapeutics climbed after a study showed positive safety and efficacy results for its muscular dystrophy treatment. The stock jumped 6.3% in morning trading Frid
Express News | Capricor Therapeutics Inc: Pre-Bla Meeting With FDA Scheduled for Q3 2024 to Discuss Options to Expedite Bla Filing
Express News | Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (Cap-1002) in Both Skeletal Muscle and Cardiac Function in the Hope-2 Ole Study in Duchenne Muscular Dystrophy